Hoth Therapeutics Reports Preclinical Results of HT-KIT in Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia
Shots:
- The research was conducted at NC State University to evaluate the efficacy of HT-KIT in cancerous and non-cancerous cells. Results demonstrated that HT-KIT effectively kills human mast cells that rely on signaling through the KIT receptor to survive and the effect of single-dose lasted for about 2wks. while reducing KIT expression lasted for 7days
- The result also demonstrated its potential to reduced KIT expression using GIST cells and kill within 48 and 72hrs. along with lower KIT expression in the AML cells over 72hrs. as well.
- HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT being developed for the treatment of mast cell-derived cancers and anaphylaxis and previously received ODD from the US FDA
Ref: PR Newswire | Image: Hoth Therapeutics
Related News:- Hoth Therapeutics Signs a License Agreement with UMB and Isoprene Pharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
